SCHEDULE 13G: Alliance Global Partners and Affiliates Disclose 9.77% Stake in Conduit Pharmaceuticals Inc.

A group including A.G.P. / Alliance Global Partners, LLC, Alliance Global Holdings, Inc., and several individuals, has disclosed a beneficial ownership of 9.77% of Conduit Pharmaceuticals Inc.'s common stock.

Summary

• A Schedule 13G filing by A.G.P. / Alliance Global Partners, LLC, Alliance Global Holdings, Inc., David Bocchi Family Trust, David A. Bocchi, Raffaele Gambardella, and Phillip W. Michals, discloses their collective beneficial ownership in Conduit Pharmaceuticals Inc.
• The reporting group beneficially owns an aggregate of 1,108,320 shares of Conduit Pharmaceuticals Inc. Common Stock.
• This aggregate amount represents 9.77% of the Issuer's Common Stock outstanding, based on 11,338,523 shares outstanding as of April 21, 2025, as reported by the Issuer in its Form S-3.
• The ownership includes 1,065,320 shares issued upon the partial conversion of a Convertible Note, 13,000 shares previously held, and 29,925 shares underlying currently exercisable warrants.
• All reporting persons share both voting and dispositive power over the 1,108,320 shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain positive or negative performance indicators or forward-looking statements that would influence sentiment.

Positives

• The disclosure of a significant ownership stake by an institutional group, including a broker-dealer, may signal confidence in Conduit Pharmaceuticals Inc. from sophisticated investors.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional and individual ownership stakes, which can influence market perception and liquidity.

Key Dates

Keywords

Conduit Pharmaceuticals Inc., A.G.P. / Alliance Global Partners, Alliance Global Holdings, SEC filing, Schedule 13G, beneficial ownership, common stock, equity stake, institutional investor